Clinical trial · Observational
Gene Expression Profiles to Categorize Wilms Tumors
Categorization of Wilms Tumors by Genetic Expression
NCT00897637CI-TRIAL-00022288completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This laboratory study is using gene expression profiling to identify different categories of Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Wilms Tumor and Other Childhood Kidney Tumors | — | UNRESOLVED | — |
| Stage III Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage II Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage IV Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage I Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
| Stage V Wilms Tumor | Wilms Tumor | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- New molecular categories of Wilms tumor identified and measured by gene expression profiles
- timeFrame
- Up to 6 years
- measure
- Identification of genes that as a whole provide strong prediction of outcomes of interest
- timeFrame
- Up to 6 years
- description
- Supervised methods such as CART or Shrunken Centroid Classifier will be used.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Specimens from patients previously enrolled as "On Study" or "Followed Biology Only" on protocol NWTSG-5 (COG-Q9401) * Study follow-up data for disease status available * National Wilms Tumor Study Group/Children's Oncology Group pathology review showing "favorable" histology * Sufficient biology samples available without using biology bank reserves
References
Publications (0)
Data not yet available
No reference posted for this study.